| Structure | Cat No. | Product Name | CAS No. | Product Description |
|---|---|---|---|---|
|
V0559 | MG-132(R) | 1211877-36-9 | MG-132 (R) (R-isomer of MG-132),a peptide aldehyde, is a novel, potent, non-specific, cell permeable and reversible inhibitor 20S proteasome inhibitor, with IC50of 24.2 nM for the β5 chymotrypsin-like active site. |
|
V0685 | MG-132 | 133407-82-6 | MG-132,a peptide aldehyde, is a novel, specific, potent, reversible, and cell-permeable inhibitor of proteasome with IC50 of 100 nM in a cell-free assay, and also inhibits calpain with IC50 of 1.2 μM. |
|
V0690 | ONX-0914 (PR-957) | 960374-59-8 | ONX-0914 (also known as ONX0914; PR957) is a selective inhibitor of LMP7 and LMP2 subunits of immunoproteasomes with the potential to be used inautoimmune diseases including rheumatoid arthritis, inflammatory bowel disease and lupus. |
|
V0694 | PI-1840 | 1401223-22-0 | PI-1840 (PI1840; PI 1840) is a reversible/non-covalent and selective inhibitor of chymotrypsin-like (CT-L) activity of proteasome with potential anticancer activity. |
|
V145675 | TCL1 | 875165-39-2 | TCL1 is a selective non-covalent inhibitor that targets the Pru domain of the Rpn-13 subunit in the proteasome 19S regulatory particle (19S RP), with an IC50 value of approximately 26 μM. |
|
V0695 | VR23 | 1624602-30-7 | VR23 (VR-23; VR 23) is a highly potent and selective inhibitor of trypsin-like proteasome with potential antitumor activity. |
|
V0686 | CARFILZOMIB (PR171) | 868540-17-4 | Carfilzomib (formerly also known as PR-171; trade name: Kyprolis) is a novel, potent, andirreversible proteasome inhibitor with potential antineoplastic activity. |
|
V0692 | DELANZOMIB (CEP18770) | 847499-27-8 | Delanzomib (formerly known asCEP-18770) is a novel, potent, and orally bioactive inhibitor of the chymotrypsin-like (CL) activity of proteasome with potential antineoplastic activity. |
|
V0688 | IXAZOMIB (MLN2238) | 1072833-77-2 | Ixazomib (formerly also known as MLN-2238) is a novel, potent, selective and reversible proteasome inhibitor (PI) with potential antineoplastic activity. |
|
V0691 | OPROZOMIB (ONX-0912) | 935888-69-0 | Oprozomib (formerly known as ONX 0912 and PR 047) is a novel, potent, and orally bioavailable small molecule inhibitor for chymotrypsin-like (CT)-L activity of 20S proteasome β5/LMP7 with potential antitumor activity. |
|
V0687 | Ixazomib citrate (MLN 9708; Ninlaro) | 1201902-80-8 | MLN9708 (also known as ixazomib citrate; MLN-9708; trade name Ninlaro),the citrate salt of Ixazomib(MMLN2238; MMLN-2238), isa prodrug of Ixazomib (MMLN-2238) which isan orally bioavailable and 2nd generation proteasome inhibitor (PI) with potential antineoplastic activity. |
|
V0684 | Bortezomib (PS-341; Velcade) | 179324-69-7 | Bortezomib (formerly also known as PS-341; trade name Velcade among others), a dipeptideboronic acid derivative, is cell-permeable, reversible, potent and highly selective inhibitor of 20S proteasome with potential antitumor activity. |
|
V0689 | EPOXOMICIN (BU 4061T) | 134381-21-8 | Epoxomicin (formerly also known as BU-4061T) is a novel, potent, selective,cell-permeable and irreversible proteasome inhibitor with anti-inflammatory activity, it inhibits primarily the CH-L activity of the 20S proteasome, while T-L and PGPH catalytic activities are also inhibited at 100- and 1000-fold reduced rate. |
|
V0693 | CELASTROL | 34157-83-0 | Celastrol (also called tripterine) is a naturally occurring pentacyclic nortriterpen quinone and a remedial ingredient found in the root extracts of Tripterygium Wilfordi (Thunder of God vine) and Celastrus Regelii. |
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
